<HashMap><database>biostudies-other</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Shakti P Pattanayak</submitter><species>Homo sapiens (human)</species><species>Mus musculus (mouse)</species><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-BSST2345</full_dataset_link><repository>biostudies-other</repository><additional_accession>https</additional_accession><pubmed_authors>William C Merrick</pubmed_authors><pubmed_authors>Belinda Willard</pubmed_authors><pubmed_authors>Timothy A. Chan</pubmed_authors><pubmed_authors>Boaz Tirosh</pubmed_authors><pubmed_authors>Hong Wang</pubmed_authors><pubmed_authors>Zheng-Rong Lu</pubmed_authors><pubmed_authors>Shakti P Pattanayak</pubmed_authors></additional><is_claimable>false</is_claimable><name>Inhibition of KDEL receptors remodels the tumor microenvironment for robust T cell independent tumor regression</name><description>Tumor immunotherapy is supported by low-grade inflammatory conditions at the microenvironment, triggered by immunogenic cell death (ICD). However, ICD is dampened when tumors acquire resistance, affecting immune recognition. KDEL receptors (KDELRs), through a retrograde Golgi-to-ER transport, prevent spontaneous secretion of KDEL proteins. We report that inhibition of a single KDELR in a minor fraction of tumor cells, primarily KDELR2, provokes robust infiltration of macrophages and neutrophils into the tumor microenvironment, resulting in a complete regression of both immunogenic and non-immunogenic tumors independently of T cells. Importantly, in the course of regression, anti-tumor T cells are primed, conferring protection against a second challenge. Recapitulated by intratumoral delive</description><dates><release>2025-12-24T00:00:00Z</release><modification>2026-05-27T12:34:44.016Z</modification><creation>2025-12-23T19:37:04.18Z</creation></dates><accession>S-BSST2345</accession><cross_references><biostudies>https</biostudies></cross_references></HashMap>